| pubmed-article:606790 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:606790 | lifeskim:mentions | umls-concept:C0029348 | lld:lifeskim |
| pubmed-article:606790 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:606790 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:606790 | lifeskim:mentions | umls-concept:C2076600 | lld:lifeskim |
| pubmed-article:606790 | pubmed:dateCreated | 1978-4-26 | lld:pubmed |
| pubmed-article:606790 | pubmed:abstractText | Seventy-nine high-risk children were immunized with either commercial, bivalent, split-product influenza A vaccine or purified hemagglutinin-neuraminidase bivalent influenza A vaccine, and 78 of these subjects were immunized with commercial, monovalent, influenza B split-product vaccine. The reactogenicity of all three vaccines was low, and there were no severe reactions. Twenty-nine subjects who received hemagglutinin-neuraminidase vaccine as their initial dose and commercial split-product vaccine as a booster dose had significantly lower antibody responses to influenza A/New Jersey/76 virus than subjects who received two doses of commercial split-product vaccine. The responses of the two groups to influenza A/Victoria/75 virus were comparable. Twenty-four subjects with malignancy who were receiving chemotherapy were compared with a group of subjects matched for age and vaccine preparation. Patients with cancer had significantly lower antibody responses to A/New Jersey/76 virus than patients without cancer. The ultimate responses of patients with cancer to A/Victoria/75 and B/Hong Kong/72 viruses were comparable to those of other patients, but early responses were lower. | lld:pubmed |
| pubmed-article:606790 | pubmed:language | eng | lld:pubmed |
| pubmed-article:606790 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:606790 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:606790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:606790 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:606790 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:606790 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:606790 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:606790 | pubmed:author | pubmed-author:ParedesAA | lld:pubmed |
| pubmed-article:606790 | pubmed:author | pubmed-author:TaberL HLH | lld:pubmed |
| pubmed-article:606790 | pubmed:author | pubmed-author:WebsterR GRG | lld:pubmed |
| pubmed-article:606790 | pubmed:author | pubmed-author:GlezenW PWP | lld:pubmed |
| pubmed-article:606790 | pubmed:author | pubmed-author:AllisonJ EJE | lld:pubmed |
| pubmed-article:606790 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:606790 | pubmed:volume | 136 Suppl | lld:pubmed |
| pubmed-article:606790 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:606790 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:606790 | pubmed:pagination | S672-6 | lld:pubmed |
| pubmed-article:606790 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-H... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-N... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-A... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-D... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-C... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-H... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-C... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-I... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-L... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-K... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-C... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-F... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-M... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-A... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-I... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-N... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-I... | lld:pubmed |
| pubmed-article:606790 | pubmed:meshHeading | pubmed-meshheading:606790-A... | lld:pubmed |
| pubmed-article:606790 | pubmed:year | 1977 | lld:pubmed |
| pubmed-article:606790 | pubmed:articleTitle | Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. | lld:pubmed |
| pubmed-article:606790 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:606790 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:606790 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:606790 | lld:pubmed |
